Plain-English translation of NCT06561178 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing whether a new type of blood test — called circulating tumor DNA (ctDNA) analysis — can predict if esophageal cancer will return after surgery and chemotherapy. The study will track patients' blood samples over time to see if changes in tumor DNA in the blood match with cancer coming back. This could help doctors decide which patients need additional treatment after surgery.
After surgery and chemotherapy, some patients with esophageal cancer still have cancer cells remaining that aren't visible on scans. Currently, doctors don't have a reliable way to know which patients are at highest risk for recurrence. This study aims to find out if monitoring this blood test can help identify those high-risk patients earlier, so they can receive additional treatment to prevent the cancer from returning.
You likely qualify if…
You likely don't qualify if…
Over the course of several months to a year, you will have blood drawn at scheduled visits — likely several times during the first few months after surgery, then at regular intervals. These blood samples will be tested for tumor DNA to track whether it is increasing, decreasing, or staying the same. You will also continue receiving standard post-surgery care and may receive immunotherapy. The study team will follow your health and watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China